XClose

Convince Hemodiafiltration Dialysis Study

Menu

Publications

Publications
It was agreed that any research that CONVINCE generates is based on a prior consensus of all members of the CONVINCE Scientific Committee. 

 

Vernooij RWM, Hockham, C, Barth C, Canaud B, Cromm K, Davenport A, Hegbrant J, Rose M, Strippoli GFM, Török M, Woodward M, Bots ML, Blankestijn PJ.; High-target haemodiafiltration convective dose achieved in the majority of patients in a 6-month intermediary analysis of the CONVINCE randomised controlled trial.  Kidney International Reports 2023 Vol 8(11) p. 2276-2283.  https://doi.org/10.1016/j.ekir.2023.08.004  

Blankestijn PJ, Vernooij RWM, Hockham C, Strippoli G, Canaud B, Hegbrant J, Barth C, Covic A, Cromm K, Cucui A, Davenport A, Rose M, Török M, Woodward M, Bots ML for the CONVINCE Scientific Committee Investigators.  Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure. New England Journal of Medicine 2023, 389 p.700-709  DOI: 10.1056/NEJMoa2304820

Liegl G, Fischer FH, Woodward M, Török M, Strippoli GFM, Hegbrant J, Davenport A, Cromm K, Canaud B, Bots ML, Blankestijn PJ, Barth C, Fischer KI, Rose M; CONVINCE Scientific Committee. Physical Performance tasks were linked to the PROMIS physical function metric in patients undergoing hemodialysis.  J. Clin Epidemiol. 2023 Vol 159, p. 128-138.   doi: 10.1016/j.clinepi.2023.04.007. 

van Kruijsdijk RCM, Vernooij RWM, Bots ML, Peters SAE, Dorresteijn JAN,  Visseren FLJ, Blankestijn PJ, Debray,TPA, The HDF Pooling Project investigators.  Personalizing treatment in end-stage kidney disease: deciding between haemodiafiltration and haemodialysis based on individualized treatment effect prediction, Clinical Kidney Journal 2022; 15(10); 1924-1931. https://doi.org/10.1093/ckj/sfac153

Vernooij RWM, Bots ML, Strippoli GFM, Canaud B, Cromm K, Woodward M, Blankestijn, PJ  CONVINCE in the context of existing evidence on haemodiafiltration Nephrol Dial Transplant 2022 37(6): 1006-1013.  doi: 10.1093/ndt/gfac019. 

Davenport A.  Comparison Between the Physical Performance Test and the Clinical Fraialty Score in Adult Patients with Chronic Kidney Disease Treated by Haeamodialysis.  Gerontol Geriatr Med. 2022  Mar 28;8:23337214221085875. doi: 10.1177/23337214221085875 eCollection 2022 Jan-Dec. 

Blankestijn PJ, Fischer KI, Barth C, Cromm K, Canaud B, Davenport A, Grobbee DE, Hegbrant J, Roes KC, Rose M, Strippoli GF, Vernooij RW, Woodward M, de Wit GA, Bots ML. Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol. BMJ OPEN, 2020, 10 (2), doi:10.1136/bmjopen-2019-033228

Blankestijn PJ, Grooteman MP, Nube MJ and Bots ML. Clinical evidence on haemodiafiltration.  Nephrology Dialysis Transplantation  2018, 33, iii53-iii58. doi: 10.1093/ndt/gfy218. 

 

Meeting Presentations

Kathrin I. Fischer, Peter J. Blankestijn, Krister Cromm, Michiel L. Bots, Claudia Barth, Bernard Canaud, Jörgen Hegbrant, Giovanni Strippoli, Andrew Davenport, Mark Woodward, Matthias Rose on behalf of the CONVINCE Consortium.  Assessing the Patient’s Perspective in End-stage Kidney Disease –ADomain-Guided Approach Applied in the CONVINCE Trial. Poster presentation at 26th Annual Conference ISOQOL, 2019. 

Fischer KI, Blankestijn PJ, Cromm K, Bots ML, Barth C, Canaud B, Hegbrant J, Macário F, Marrón B, Török M, Davenport A, Lee MM, Strippoli GFM, Wohn L, Woodward M, Rose M. Assessment of generic and dialysis-related fatigue – Identification of individual trajectories and investigation of ecological validity. Quality of Life Research. 2020;29(S1): S180.  https://doi.org/10.1007/s11136-020-02626-y    link to abstract.  Poster presentation at 27th Annual Conference ISOQOL, 2020.

Robin W.M. Vernooij, on behalf of the CONVINCE Study Group “The comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) study” presentation at the 58th ERA-EDTA Congress in Berlin, June 2021.  Nephrology Dialysis Transplantation, Volume 36, Issue Supplement_1, May 2021, gfab098.004, https://doi.org/10.1093/ndt/gfab098.004

Gregor Liegl, Felix H. Fischer, Peter J. Blankestijn, Krister Cromm, Michiel L. Bots, Matthias Rose, on behalf of the CONVINCE Scientific Committee, Can patient-reported and performance outcome measures be used to assess a common construct of general physical function in patients undergoing hemodialysis? Oral presentation at the ISOQOL 2022 Prague. https://link.springer.com/article/10.1007/s11136-022-03257-1

Le Hong Ngoc Pham, Krister Cromm, Yan Zhang, Anna Schappert, Gregor Liegl, Kathrin I. Fischer, Felix Fischer and Matthias Rose. Psychometric validation of the CONVINCE inter- & intradialytic symptoms questionnaire.  American Society of Nephrology  Accepted as poster presentation at the 56th Annual Meeting of the American Society of Nephrology in Pennsylvania USA 1-5 November 2023.

Krister Cromm, Le Hong Ngoc Pham, Hanna Jaha, Anna Schappert, Gregor Liegl, Kathrin I. Fischer, Felix Fischer, Matthias Rose. Self-Efficacy and Social Support Determine Self-Reported Health in hemodialysis patients. Accepted as oral presentation at the 56th Annual Meeting of the American Society of Nephrology in Pennsylvania USA 1-5 November 2023.

Blankestijn PJ, Vernooij RWM, Hockham C, Strippoli GFM, Barth C, Canaud B, Covic A, Cromm K, Cucui AM, Davenport A, Hegbrant J, Rose M, Sanchez Torres D, Török M, Woodward M, Bots ML, for the CONVINCE Scientific Committee and CONVINCE Investigators.  CONVINCE: Haemodiafiltration versus haemodialysis for mortality, cardiovascular events, and hospitalisation in adult patients.  ERA 2023.

Krister Cromm, Le Hong Ngoc Pham, Hanna Jaha, Anna Schappert, Gregor Liegl, Felix Fischer, Matthias Rose. Self-Efficacy Explains Health-Related Quality of Life on Dialysis more than Social Support, Medical and Demographic Patient Characteristics. ISOQOL 2023, Calgary, Canada.